Get the Stockscreener App
2.6078
4.18%
0.0978
Pacific Biosciences Of California Inc stock is traded at $2.6078, with a volume of 7.95M.
It is up +4.18% in the last 24 hours and up +52.03% over the past month.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
See More
Previous Close:
$2.51
Open:
$2.45
24h Volume:
7.95M
Relative Volume:
1.00
Market Cap:
$695.17M
Revenue:
$188.87M
Net Income/Loss:
$-400.38M
P/E Ratio:
-2.0534
EPS:
-1.27
Net Cash Flow:
$-260.90M
1W Performance:
+26.94%
1M Performance:
+52.03%
6M Performance:
+42.90%
1Y Performance:
-63.78%
1-Day Range:
$2.405
$2.65
1-Week Range:
$2.015
$2.65
52-Week Range:
$1.16
$10.65
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Name
Pacific Biosciences Of California Inc
Sector
Industry
Phone
650-521-8000
Address
1305 O'BRIEN DRIVE, MENLO PARK, CA
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-17-23 | Upgrade | UBS | Neutral → Buy |
| Oct-31-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jun-30-23 | Initiated | Goldman | Buy |
| May-10-23 | Initiated | Barclays | Equal Weight |
| Mar-31-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Feb-02-23 | Initiated | UBS | Neutral |
| Jan-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-21-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-06-22 | Resumed | Piper Sandler | Neutral |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Sep-27-21 | Initiated | Canaccord Genuity | Buy |
| Feb-11-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-03-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-02-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-02-20 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-09-20 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-15-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-02-19 | Downgrade | Stephens | Overweight → Equal-Weight |
| Oct-19-18 | Initiated | Cowen | Outperform |
| Nov-03-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Sep-28-17 | Downgrade | CL King | Buy → Neutral |
| Nov-03-16 | Reiterated | Cantor Fitzgerald | Buy |
| Jun-27-16 | Initiated | CL King | Buy |
| Apr-15-16 | Initiated | First Analysis Sec | Overweight |
| Feb-04-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jan-04-16 | Reiterated | Cantor Fitzgerald | Buy |
| Oct-23-15 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-27-15 | Initiated | Cantor Fitzgerald | Buy |
| Feb-04-15 | Reiterated | Maxim Group | Buy |
| Sep-26-13 | Reiterated | Maxim Group | Buy |
| Jan-14-13 | Reiterated | Maxim Group | Buy |
View All
Pacific Biosciences Of California Inc Stock (PACB) Latest News
Vanguard Group Inc's Strategic Reduction in Pacific Biosciences of California Inc - GuruFocus.com
Reasons to Retain PacBio Stock in Your Portfolio for Now - MSN
Curious about Pacific Biosciences (PACB) Q3 Performance? Explore Wall Street Estimates for Key Metrics - Yahoo Finance
Assenagon Asset Management S.A. Trims Stock Position in Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat
Pacific Biosciences of California (PACB) Advances While Market Declines: Some Information for Investors - Yahoo Finance
Pacific Biosciences of California (PACB) Scheduled to Post Earnings on Thursday - MarketBeat
Pacific Biosciences (PACB): Promising Gene Editing Stock With Innovating Technology - Insider Monkey
Volta Labs joins PacBio Compatible program to help PacBio customers scale sequencing through automated library prep - Quantisnow
Pacific Biosciences of California (NASDAQ:PACB) Shares Up 5.7%Should You Buy? - MarketBeat
PacBio unveils new sequencing chemistry to cut costs By Investing.com - Investing.com Canada
PacBio Announces SPRQ Chemistry for Revio Sequencing Systems, a Major Advance Reducing the Cost of a HiFi Human Genome to less than $500 - Quantisnow
Pacific Biosciences of California, Inc. (NASDAQ:PACB) is a favorite amongst institutional investors who own 86% - Yahoo Finance
PACB (Pacific Biosciences of California) Cash-to-Debt : 0.55 (As of Jun. 2024) - GuruFocus.com
PacBio Onso™ Short Read Sequencing Instrument Joins 10x Genomics Compatible Partner Program - StockTitan
PacBio Shares Rise After NCCS Partnership for Cancer Genomics Research - MSN
Pacific Biosciences of California (PACB) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance
Pacific Biosciences of California (NASDAQ:PACB) Trading Down 4.8%Here's Why - MarketBeat
Health Check: How Prudently Does Pacific Biosciences of California (NASDAQ:PACB) Use Debt? - Simply Wall St
Brokerages Set Pacific Biosciences of California, Inc. (NASDAQ:PACB) PT at $4.50 - MarketBeat
Pacific Biosciences of California (NASDAQ:PACB) Shares Gap DownHere's Why - MarketBeat
Dimensional Fund Advisors LP Sells 2,121,331 Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat
PacBio inks cancer research deal with Singapore's NCCS By Investing.com - Investing.com South Africa
PacBio inks cancer research deal with Singapore's NCCS - Investing.com India
Pacific Biosciences of California (NASDAQ:PACB) Trading 18.4% HigherHere's Why - MarketBeat
PacBio Enters Cancer Genomics Research Collaboration in Singapore with Advanced Onso Sequencing - StockTitan
PacBio to Report Third Quarter 2024 Financial Results on November 7, 2024 - GlobeNewswire
Squarepoint Ops LLC Purchases Shares of 524,608 Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat
Marshall Wace LLP Raises Stake in Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) - MSN
PacBio, A*STAR, and Macrogen Unveil State-of-the-Art Lab to Accelerate Genomics Innovation in Singapore - StockTitan
PacBio's SWOT analysis: genomics firm faces headwinds, seeks growth - Investing.com
PacBio Grants Equity Incentive Award to New Employee - Quantisnow
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Shares Sold by Oracle Investment Management Inc. - MarketBeat
Pacific Biosciences of California (NASDAQ:PACB) Shares Gap Down to $2.04 - MarketBeat
Even With A 37% Surge, Cautious Investors Are Not Rewarding Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Performance Completely - Simply Wall St
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Receives $4.50 Average Price Target from Analysts - MarketBeat
RNA sequencing with Kinnex kits transforms University of Southampton rare disease research - Pacific Biosciences
A stock that deserves closer examination: Pacira BioSciences Inc (PCRX) - US Post News
OrbiMed Advisors sells shares of Passage Bio worth over $146,000 - Investing.com
Pacific Biosciences of California (NASDAQ:PACB) Shares Gap Up to $1.87 - MarketBeat
Stocks of Pacific Biosciences of California Inc (PACB) are poised to climb above their peers - SETE News
Riding the Waves: A Guide to Investing in PCRX Stock - The InvestChronicle
Processa Pharmaceuticals (NASDAQ:PCSA) Stock Price Down 0.7% - Defense World
Health Check: Paradigm receives FDA guidance on proposed trial for dodgy knees - Stockhead
Guess which ASX biotech stock is surging 11% on big FDA news - The Motley Fool Australia
Analysts review Pacira BioSciences Inc’s rating - Knox Daily
The time has not yet come to remove your chips from the table: PACS Group Inc. (PACS) - SETE News
Insider’s View: Deciphering Pacira BioSciences Inc (PCRX)’s Financial Health Through Ratios - The Dwinnex
Pacific Biosciences of California Inc’s Mixed Bag: Down -51.19% in 6 Months, Down 9.47% in 30 Days - The InvestChronicle
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Shares Purchased by Daiwa Securities Group Inc. - Defense World
Pacific Biosciences Of California Inc Stock (PACB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.55%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):